A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Pazopanib (Primary) ; Ranibizumab
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Sponsors ForSight VISION4
- 06 Oct 2019 Status changed from recruiting to discontinued.
- 10 Jan 2017 This trial was being conducted by ForSight VISION4. The Company has now been acquired by Roche, according to a ForSight VISION4 media release.
- 30 Nov 2016 New trial record